Aerie Pharmaceuticals, Inc.AERI announced positive results from a phase III study (Rocket 2) on Rhopressa, which is being evaluated for its ability in lowering intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Both the once and twice